2 Value Stocks to Dive Into Now: Neos Therapeutics, Inc. (NEOS), Broadcom Inc. (AVGO)

Neos Therapeutics, Inc. (NASDAQ:NEOS) is simply too cheap to pass with a price-to-sales ratio of 2.17. The competitors from Drugs – Generic hold an average P/S ratio of 13.11, which offer discount compared with the sector’s 14.27. In the past 5-year record, this ratio went down as low as 1.79 and as high as 126.13. Also, it is down from 0.7 of the total 775 rivals across the globe.

NEOS traded at an unexpectedly high level on 11/06/2018 when the stock experienced a -2.99% loss to a closing price of $2.6. The company saw 3.3 million shares trade hands over the course of the day. Given that its average daily volume over the 30 days has been 293.18 million shares a day, this signifies a pretty significant change over the norm.

Neos Therapeutics, Inc. (NEOS) Analyst Gushes

Analysts are speculating a 746.15% move, based on the high target price ($22) for the shares that is set to reach in the next 12 months. The analysts, on average, are forecasting a $16.2 price target, but the stock is already up -2.8% from its recent lows. However, the stock is trading at -79.03% versus recent highs ($12.4). Analysts believe that we could see stock price minimum in the $8 range (lowest target price), allowing for another 207.69% jump from its current position. Leading up to this report, we have seen a -37.8% fall in the stock price over the last 30 days and a -57.02% decline over the past 3 months. Overall, the share price is down -74.51% so far this year. Additionally, NEOS had a day price range of $2.2703 to $2.72.

Neos Therapeutics, Inc. (NEOS) Price Potential

Heading into the stock price potential, Neos Therapeutics, Inc. needs to grow just 669.23% to cross its median price target of $20. In order to determine directional movement, the 50-day and 200-day moving averages for Neos Therapeutics, Inc. (NASDAQ:NEOS) are $4.23 and $5.9. Given that liquidity is king in short-term, NEOS is a stock with 32.26 million shares outstanding that normally trades 7.96% of its float. The stock price recently experienced a 5-day loss of -22.85% with 0.3 average true range (ATR). NEOS has a beta of 0.42 and RSI is 14.02.

Investors also need to beware of the Broadcom Inc. (NASDAQ:AVGO) valuations. The stock trades on a P/S of 5.92, which suggests that the shares are attractive compared with peers. The broad Semiconductor – Broad Line industry has an average P/S ratio of 11.88, which is significantly worse than the sector’s 2.87. In the past 11-year record, this ratio went down as low as 2.24 and as high as 6.93. Also, it is down from 0.84 of the total 832 rivals across the globe.

Broadcom Inc. (AVGO)’s Lead Over its Technicals

Broadcom Inc. by far traveled 15.59% versus a 1-year low price of $197.46. The share price was last seen 3.71% higher, reaching at $228.25 on Nov. 06, 2018. At recent session, the prices were hovering between $219.72 and $229.16. This company shares are 26.62% off its target price of $289 and the current market capitalization stands at $98.26B. The recent change has given its price a -1.7% deficit over SMA 50 and -20.1% deficit over its 52-week high. The stock witnessed -5.44% declines, 4.01% gains and -4.12% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found AVGO’s volatility during a week at 3.6% and during a month it has been found around 3.44%.

Broadcom Inc. (NASDAQ:AVGO) Intraday Metrics

Broadcom Inc. (AVGO) exchanged hands at an unexpectedly low level of 2.94 million shares over the course of the day. Noting its average daily volume at 3.71 million shares each day over the month, this signifies a pretty significant change over the norm.

Broadcom Inc. Target Levels

The market experts are predicting a 62.1% rally, based on the high target price ($370) for Broadcom Inc. shares that is likely to be hit in the 52 weeks. Analysts anticipate that traders could see stock price minimum in the $230 range (lowest target price). If faced, it would be a 0.77% jump from its current position. Overall, the share price is down -11.15% year to date.